DE69739172D1
(de)
|
1996-08-08 |
2009-01-29 |
Amylin Pharmaceuticals Inc |
Regulation gastrointestinaler beweglichkeit
|
DE122007000044I2
(de)
*
|
1997-01-07 |
2011-05-05 |
Amylin Pharmaceuticals Inc |
Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
|
US7157555B1
(en)
*
|
1997-08-08 |
2007-01-02 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
WO1999007404A1
(en)
*
|
1997-08-08 |
1999-02-18 |
Amylin Pharmaceuticals, Inc. |
Novel exendin agonist compounds
|
ATE383867T1
(de)
†
|
1997-11-14 |
2008-02-15 |
Amylin Pharmaceuticals Inc |
Neuartige exendin agonisten
|
EP1938830A1
(en)
*
|
1997-11-14 |
2008-07-02 |
Amylin Pharmaceuticals, Inc. |
Novel exendin agonist compounds
|
US7220721B1
(en)
*
|
1997-11-14 |
2007-05-22 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist peptides
|
EP1941900A1
(en)
*
|
1997-11-14 |
2008-07-09 |
Amylin Pharmaceuticals, Inc. |
Novel exendin agonist compounds
|
ATE381939T1
(de)
*
|
1997-11-14 |
2008-01-15 |
Amylin Pharmaceuticals Inc |
Neuartige exendin agonisten
|
AU3247799A
(en)
|
1998-02-27 |
1999-09-15 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
DE69942305D1
(de)
|
1998-02-27 |
2010-06-10 |
Novo Nordisk As |
Derivate von glp-1 und exendin mit verlängertem wirkdauer-profil
|
NZ527473A
(en)
|
1998-06-12 |
2005-02-25 |
Amylin Pharmaceuticals Inc |
Glucagon-like peptide-1 improves beta-cell response to glucose in subjects with impaired glucose tolerance
|
JP2002523333A
(ja)
|
1998-07-31 |
2002-07-30 |
ノボ ノルディスク アクティーゼルスカブ |
Ii型糖尿病を予防するためのglp−1及び類似体の利用
|
AU770712B2
(en)
*
|
1999-01-14 |
2004-02-26 |
Amylin Pharmaceuticals, Inc. |
Methods for glucagon suppression
|
EP1609478A1
(en)
*
|
1999-01-14 |
2005-12-28 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist peptide formulations
|
US7399489B2
(en)
|
1999-01-14 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Exendin analog formulations
|
US6605648B1
(en)
*
|
1999-04-06 |
2003-08-12 |
Phillips Plastics Corporation |
Sinterable structures and method
|
CN1372570A
(zh)
|
1999-04-30 |
2002-10-02 |
安米林药品公司 |
修饰的exendin和exendin激动剂
|
US6924264B1
(en)
|
1999-04-30 |
2005-08-02 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
SI1180121T1
(en)
|
1999-05-17 |
2004-04-30 |
Conjuchem, Inc. |
Long lasting insulinotropic peptides
|
US6514500B1
(en)
*
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
US20090175821A1
(en)
*
|
1999-05-17 |
2009-07-09 |
Bridon Dominique P |
Modified therapeutic peptides with extended half-lives in vivo
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
US6844321B2
(en)
|
2000-01-31 |
2005-01-18 |
Novo Nordisk A/S |
Crystallization of a GLP-1 analogue
|
EP1263458B1
(en)
|
2000-03-08 |
2005-11-16 |
Novo Nordisk A/S |
Lowering serum cholesterol
|
CN1501809B
(zh)
*
|
2000-12-13 |
2012-10-10 |
伊莱利利公司 |
应用胰高血糖素样促胰岛肽的长期治疗方案
|
AU2002233089B2
(en)
|
2001-02-16 |
2005-12-22 |
Conjuchem Biotechnologies Inc. |
Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders
|
AU2002317599B2
(en)
|
2001-07-31 |
2008-04-03 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
GLP-1 exendin-4 peptide analogs and uses thereof
|
US7544657B2
(en)
*
|
2002-10-02 |
2009-06-09 |
Zealand Pharma A/S |
Stabilized Exendin-4 compounds
|
AU2003282955A1
(en)
*
|
2002-10-17 |
2004-05-04 |
Alkermes Controlled Therapeutics, Inc. Ii |
Microencapsulation and sustained release of biologically active polypeptides
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
US8008255B2
(en)
*
|
2003-05-30 |
2011-08-30 |
Amylin Pharmaceuticals, Inc. |
Methods and compositions for enhanced transmucosal delivery of peptides and proteins
|
US8263084B2
(en)
|
2003-11-13 |
2012-09-11 |
Hanmi Science Co., Ltd |
Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
|
KR101135244B1
(ko)
*
|
2007-11-29 |
2012-04-24 |
한미사이언스 주식회사 |
인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
|
RU2421238C2
(ru)
|
2003-11-20 |
2011-06-20 |
Ново Нордиск А/С |
Пептидная композиция, содержащая пропиленгликоль, являющаяся оптимальной для изготовления и применения в инъекционных устройствах
|
EP1694356B1
(en)
|
2003-12-09 |
2011-02-16 |
Novo Nordisk A/S |
Regulation of food preference using glp-1 agonists
|
US20060074025A1
(en)
*
|
2003-12-26 |
2006-04-06 |
Nastech Pharmaceutical Company Inc. |
Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
|
US20050143303A1
(en)
*
|
2003-12-26 |
2005-06-30 |
Nastech Pharmaceutical Company Inc. |
Intranasal administration of glucose-regulating peptides
|
US20080318837A1
(en)
*
|
2003-12-26 |
2008-12-25 |
Nastech Pharmaceutical Company Inc. |
Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
|
US20060210614A1
(en)
*
|
2003-12-26 |
2006-09-21 |
Nastech Pharmaceutical Company Inc. |
Method of treatment of a metabolic disease using intranasal administration of exendin peptide
|
CN1956998B
(zh)
*
|
2004-04-23 |
2012-12-12 |
康久有限责任公司 |
用于纯化白蛋白结合物的方法
|
EP1758575A1
(en)
|
2004-06-11 |
2007-03-07 |
Novo Nordisk A/S |
Counteracting drug-induced obesity using glp-1 agonists
|
AU2012202855B2
(en)
*
|
2004-09-03 |
2015-02-26 |
Philipps-Universitat Marburg |
GLP-1 and exendin related invention
|
DE102004043153B4
(de)
*
|
2004-09-03 |
2013-11-21 |
Philipps-Universität Marburg |
Erfindung betreffend GLP-1 und Exendin
|
JP4785206B2
(ja)
*
|
2005-01-14 |
2011-10-05 |
ウクスィ・グランドチャンプ・ファーマシューティカル・テクノロジー・カンパニー・リミテッド |
修飾されたエキセンディン(Exendins)及びその使用
|
US8716221B2
(en)
|
2005-01-14 |
2014-05-06 |
Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. |
Modified exendins and uses thereof
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
CN100429227C
(zh)
*
|
2005-06-29 |
2008-10-29 |
常州制药厂有限公司 |
Exendin4多肽片段
|
EP1959986B1
(en)
|
2005-11-07 |
2014-07-23 |
Indiana University Research and Technology Corporation |
Glucagon analogs exhibiting physiological solubility and stability
|
US8039432B2
(en)
*
|
2005-11-09 |
2011-10-18 |
Conjuchem, Llc |
Method of treatment of diabetes and/or obesity with reduced nausea side effect
|
WO2007061434A2
(en)
*
|
2005-11-10 |
2007-05-31 |
Nastech Pharmaceutical Company Inc. |
A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome
|
JP2009520693A
(ja)
*
|
2005-12-08 |
2009-05-28 |
エムディーアールエヌエー,インコーポレイテッド |
安定化されたエキセンディン製剤の粘膜送達
|
CN101384623B
(zh)
*
|
2005-12-22 |
2013-07-24 |
常山凯捷健生物药物研发(河北)有限公司 |
白蛋白与治疗剂的预成型偶联物的制备方法
|
KR101106510B1
(ko)
|
2006-05-30 |
2012-01-20 |
인타르시아 세라퓨틱스 인코포레이티드 |
투피스, 내부채널 삼투압 전달 시스템 유동 조절기
|
DK2049081T3
(da)
|
2006-08-09 |
2013-02-25 |
Intarcia Therapeutics Inc |
Osmotiske leveringssystemer og stempelarrangementer
|
RU2413528C2
(ru)
|
2007-01-18 |
2011-03-10 |
Открытое Акционерное Общество "Валента Фармацевтика" |
Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
|
BRPI0807728A2
(pt)
|
2007-02-15 |
2012-04-17 |
Univ Indiana Res & Tech Corp |
co-agonistas de receptor glucagon/glp-1
|
KR100746658B1
(ko)
|
2007-04-23 |
2007-08-06 |
성균관대학교산학협력단 |
소수성 담즙산이 접합된 엑센딘-4 유도체, 이의 제조방법및 이를 포함하는 약학 조성물
|
ES2402172T3
(es)
|
2007-04-23 |
2013-04-29 |
Intarcia Therapeutics, Inc |
Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
|
JP2009019027A
(ja)
|
2007-07-16 |
2009-01-29 |
Hanmi Pharmaceutical Co Ltd |
アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
|
US20100256056A1
(en)
*
|
2007-09-07 |
2010-10-07 |
Zheng Xin Dong |
Analogues of exendin-4 and exendin-3
|
ES2558155T3
(es)
|
2007-10-30 |
2016-02-02 |
Indiana University Research And Technology Corporation |
Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1
|
US20090186819A1
(en)
*
|
2007-12-11 |
2009-07-23 |
Marieve Carrier |
Formulation of insulinotropic peptide conjugates
|
EP2240155B1
(en)
|
2008-02-13 |
2012-06-06 |
Intarcia Therapeutics, Inc |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
US20090221453A1
(en)
*
|
2008-02-29 |
2009-09-03 |
Sumitra Mukhopadhyay |
Treatment Fluid With Oxidizer Breaker System and Method
|
AU2009260302B2
(en)
|
2008-06-17 |
2014-10-23 |
Indiana University Research And Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
JP6108659B2
(ja)
|
2008-06-17 |
2017-04-05 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation |
代謝疾患および肥満の治療のためのgipに基づいた混合アゴニスト
|
KR101820024B1
(ko)
|
2008-10-17 |
2018-01-18 |
사노피-아벤티스 도이칠란트 게엠베하 |
인슐린과 glp-1 효능제의 병용물
|
JP5756407B2
(ja)
|
2008-12-08 |
2015-07-29 |
ノヴォ ノルディスク アー/エス |
ポリペプチドの向流精製
|
PE20120332A1
(es)
|
2008-12-19 |
2012-04-14 |
Univ Indiana Res & Tech Corp |
Profarmacos de peptido de la superfamilia de glucagon basado en amida
|
CN101463078B
(zh)
*
|
2009-01-12 |
2011-07-27 |
华东师范大学 |
一种Exendin-4衍生物及其固相化学合成
|
MX2011013625A
(es)
|
2009-06-16 |
2012-01-20 |
Univ Indiana Res & Tech Corp |
Compuestos glucagon activo de receptor de gip.
|
CN107638562B
(zh)
|
2009-09-28 |
2022-12-02 |
精达制药公司 |
基本稳态药物递送的快速建立和/或终止
|
ES2534191T3
(es)
|
2009-11-13 |
2015-04-20 |
Sanofi-Aventis Deutschland Gmbh |
Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
|
HUE037735T2
(hu)
|
2009-11-13 |
2018-09-28 |
Sanofi Aventis Deutschland |
DesPro36exendin-4(1-39)-Lys6-NH2-t és metionint tartalmazó gyógyszerkészítmény
|
EP2504019A2
(en)
|
2009-11-25 |
2012-10-03 |
ArisGen SA |
Mucosal delivery composition comprising a peptide complexed with a crown compound and/or a counter ion
|
US8703701B2
(en)
*
|
2009-12-18 |
2014-04-22 |
Indiana University Research And Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
CA2788304A1
(en)
|
2010-01-27 |
2011-08-04 |
Indiana University Research And Technology Corporation |
Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity
|
WO2011107447A1
(en)
|
2010-03-01 |
2011-09-09 |
Novo Nordisk A/S |
Preparative rp-hplc method for purifying peptides
|
EP2555791B1
(en)
|
2010-04-09 |
2017-11-01 |
Sinai Health System |
Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
|
US9089538B2
(en)
|
2010-04-27 |
2015-07-28 |
Zealand Pharma A/S |
Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
|
BR112013004756B1
(pt)
|
2010-08-30 |
2020-04-28 |
Sanofi Aventis Deutschland |
uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2
|
WO2012088116A2
(en)
|
2010-12-22 |
2012-06-28 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting gip receptor activity
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
US9257267B2
(en)
|
2011-03-31 |
2016-02-09 |
Dh Technologies Development Pte. Ltd. |
Composition, method, and kit for calibrating a mass spectrometer
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
EP2723367B1
(en)
|
2011-06-22 |
2017-05-03 |
Indiana University Research and Technology Corporation |
Glucagon/glp-1 receptor co-agonists
|
JP6184404B2
(ja)
|
2011-06-22 |
2017-08-23 |
インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション |
グルカゴン/glp−1レセプターコアゴニスト
|
RU2650616C2
(ru)
|
2011-08-29 |
2018-04-16 |
Санофи-Авентис Дойчланд Гмбх |
Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
JP6359972B2
(ja)
|
2011-11-03 |
2018-07-18 |
ジーランド ファーマ アクティーゼルスカブ |
Glp−1受容体アゴニストペプチドガストリンコンジュゲート
|
EP2788027A2
(en)
|
2011-12-09 |
2014-10-15 |
Novo Nordisk A/S |
Glp-1 agonists
|
EP2851429B1
(en)
|
2012-05-18 |
2019-07-24 |
Adda Biotech Inc. |
Protein and protein conjugate for diabetes treatment, and applications thereof
|
JP6311708B2
(ja)
|
2012-06-21 |
2018-04-18 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation |
Gip受容体活性を示すグルカゴンアナローグ
|
CN104662038B
(zh)
|
2012-07-23 |
2018-11-06 |
西兰制药公司 |
胰高血糖素类似物
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
KR20140088837A
(ko)
|
2013-01-03 |
2014-07-11 |
한미약품 주식회사 |
N-말단 전하가 변형된 인슐린 분비 펩티드 유도체
|
TWI641381B
(zh)
|
2013-02-04 |
2018-11-21 |
法商賽諾菲公司 |
胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
|
KR102569036B1
(ko)
|
2013-10-17 |
2023-08-23 |
질랜드 파마 에이/에스 |
아실화된 글루카곤 유사체
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
US10131702B2
(en)
|
2013-11-06 |
2018-11-20 |
Zealand Pharma A/S |
Glucagon-GLP-1-GIP triple agonist compounds
|
CN105849122B
(zh)
|
2013-11-06 |
2021-04-30 |
西兰制药公司 |
Gip-glp-1双重激动剂化合物及方法
|
WO2015081891A1
(en)
|
2013-12-06 |
2015-06-11 |
Baikang (Suzhou) Co., Ltd |
Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
|
US9895424B2
(en)
|
2014-01-09 |
2018-02-20 |
Sanofi |
Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
US9839692B2
(en)
|
2014-01-09 |
2017-12-12 |
Sanofi |
Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
SG11201604706TA
(en)
|
2014-01-09 |
2016-07-28 |
Sanofi Sa |
Stabilized pharmaceutical formulations of insulin aspart
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
RU2716985C2
(ru)
|
2014-10-29 |
2020-03-17 |
Зилэнд Фарма А/С |
Соединения-агонисты gip и способы
|
JP6970615B2
(ja)
|
2014-12-12 |
2021-11-24 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
インスリングラルギン/リキシセナチド固定比処方
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患治療
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患之治療
|
RU2735762C2
(ru)
|
2015-04-16 |
2020-11-06 |
Зилэнд Фарма А/С |
Ацилированный аналог глюкагона, его применение и способы получения
|
US10925639B2
(en)
|
2015-06-03 |
2021-02-23 |
Intarcia Therapeutics, Inc. |
Implant placement and removal systems
|
CN105753963B
(zh)
*
|
2016-04-13 |
2019-08-30 |
中国药科大学 |
高活性艾塞那肽类似物及其医药应用
|
BR112018073511A2
(pt)
|
2016-05-16 |
2019-03-26 |
Intarcia Therapeutics, Inc. |
polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
AU2017371516C1
(en)
|
2016-12-09 |
2021-09-02 |
Zealand Pharma A/S |
Acylated GLP-1/GLP-2 dual agonists
|
MX2019008006A
(es)
|
2017-01-03 |
2019-08-29 |
Intarcia Therapeutics Inc |
Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.
|
CN109485720A
(zh)
*
|
2017-09-11 |
2019-03-19 |
中国药科大学 |
口服降血糖多肽、其脂肪酸修饰衍生物以及用途
|
CN115947849A
(zh)
|
2018-12-21 |
2023-04-11 |
江苏恒瑞医药股份有限公司 |
双特异性蛋白
|
CN116606367A
(zh)
*
|
2022-05-31 |
2023-08-18 |
南京盛德瑞尔医药科技有限公司 |
长效Exendin-9-39及其在低血糖治疗中的应用和作为治疗低血糖的药物
|